Comparative efficacy of intramuscular meglumine antimoniate and miltefosine in the management of cutaneous leishmaniasis
Comparative efficacy of intramuscular meglumine antimoniate and miltefosine in the management of cutaneous leishmaniasis in patients aged 18 - 60 years old.
Dr Mehran Khan - Khyber Teaching Hospital Peshawar
126 participants
Oct 1, 2025
Interventional
Conditions
Summary
to compare the efficacy of intramuscular meglumine antimonate and oral mitefosine in the management of cutaneous leishmaniasis based on the hypothesis that there is a difference in the efficacy of the two drugs mentioned.
Eligibility
Inclusion Criteria3
- age range (18-60) years
- both male and female
- cases of cutaneous leishmaniasis as mentioned in the operational definition
Exclusion Criteria3
- patients with liver and renal disease
- pregnant patients
- patients with hypersensitivity towards meglumine antimoniate or miltefosine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
patients in group A will be treated with intramuscular meglumine antimoniate in the dosage of 15-20 mg/kg/day for 4 weeks. General physician will administer the injections. patients in group B will be treated with oral miltefosine 50mg tablet twice per day in 1st week and then three times per day for the next three weeks (for total of 4 weeks).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12626000038392